{"id":36057,"date":"2022-01-12T12:15:44","date_gmt":"2022-01-12T12:15:44","guid":{"rendered":"https:\/\/www.elza-institute.com\/?p=36057"},"modified":"2024-07-15T09:22:15","modified_gmt":"2024-07-15T09:22:15","slug":"landmark-pack-cxl-trial-published","status":"publish","type":"post","link":"https:\/\/www.elza-institute.com\/pt\/landmark-pack-cxl-trial-published\/","title":{"rendered":"Publica\u00e7\u00e3o do estudo de refer\u00eancia PACK-CXL"},"content":{"rendered":"<p>Hoje, foi publicado um estudo de refer\u00eancia sobre o PACK-CXL que demonstra que o PACK-CXL \u00e9 uma terapia eficaz contra a infe\u00e7\u00e3o da c\u00f3rnea.<\/p>\n<p>Os autores pretendiam saber se o reticulado corneano crom\u00f3foro fotoactivado aut\u00f3nomo (PACK-CXL) pode ser um tratamento de primeira linha eficaz na ceratite infecciosa inicial a moderada, em compara\u00e7\u00e3o com o tratamento antimicrobiano padr\u00e3o. Para o efeito, realizaram um grande ensaio cl\u00ednico internacional, multic\u00eantrico, de fase III, que envolveu doentes com ceratite infecciosa que se pensava ser causada por bact\u00e9rias, fungos ou uma mistura dos dois. O que procuravam era o \"sucesso do tratamento\" - a resolu\u00e7\u00e3o completa de qualquer sinal de infe\u00e7\u00e3o - e o tempo de reepiteliza\u00e7\u00e3o (quando as c\u00e9lulas protectoras na parte superior da c\u00f3rnea voltam a crescer). Os doentes com \u00falceras da c\u00f3rnea foram tratados apenas com o PACK-CXL ou com terapia antimicrobiana padr\u00e3o.<\/p>\n<p>Ambos os tratamentos tiveram um sucesso semelhante e elevado: 88,9% dos pacientes tratados com PACK-CXL e 90,5% dos pacientes tratados com terapia antimicrobiana tiveram sucesso no tratamento, e n\u00e3o houve diferen\u00e7a no tempo de reepiteliza\u00e7\u00e3o entre os grupos de tratamento.<\/p>\n<p>A import\u00e2ncia destes resultados n\u00e3o pode ser subestimada: existe uma grande necessidade n\u00e3o satisfeita de terapias eficazes contra a queratite infecciosa (infe\u00e7\u00e3o da c\u00f3rnea), que \u00e9 uma das principais causas de cegueira a n\u00edvel mundial. Esta situa\u00e7\u00e3o insere-se num contexto de crescente resist\u00eancia aos medicamentos antimicrobianos. Por exemplo, o \u00faltimo antibi\u00f3tico novo foi descoberto em 1987, e as bact\u00e9rias t\u00eam continuado a desenvolver resist\u00eancia aos medicamentos de que dispomos atualmente para as tratar.<\/p>\n<p>Mas h\u00e1 outro benef\u00edcio importante que o PACK-CXL tem em rela\u00e7\u00e3o ao tratamento antimicrobiano: o tempo do m\u00e9dico. O PACK-CXL pode tratar com \u00eaxito a maioria dos casos com um \u00fanico tratamento. A terapia antimicrobiana requer um tratamento intensivo, de hora a hora, 24 horas por dia, com acompanhamento frequente e regular de um m\u00e9dico. Nos pa\u00edses em desenvolvimento, este n\u00edvel de cuidados est\u00e1 muitas vezes fora do alcance da maioria da popula\u00e7\u00e3o por v\u00e1rias raz\u00f5es:<\/p>\n<ul>\n<li><strong>O custo \u00e9 proibitivo<\/strong>. Mesmo que um doente possa pagar o primeiro tratamento, poder\u00e1 n\u00e3o ter dinheiro para as consultas seguintes. Esta \u00e9 claramente uma situa\u00e7\u00e3o m\u00e1, uma vez que o doente necessita de uma terapia intensiva e frequente para que o tratamento seja eficaz.<\/li>\n<li><strong>Acesso aos m\u00e9dicos<\/strong> <strong>\u00e9 limitado<\/strong>. A maioria dos oftalmologistas nos pa\u00edses em desenvolvimento est\u00e1 localizada nos grandes centros populacionais, onde se encontram os hospitais. A maior parte da popula\u00e7\u00e3o vive em zonas rurais distantes.<\/li>\n<li><b>A perda de vis\u00e3o equivale \u00e0 perda de meios de subsist\u00eancia.<\/b> A maioria das pessoas nos pa\u00edses em desenvolvimento trabalha na agricultura e a perda de vis\u00e3o pode impedir gravemente as pessoas de continuarem a fazer esse trabalho. Pior ainda, uma das causas mais comuns de ceratite infecciosa s\u00e3o os fungos introduzidos na c\u00f3rnea atrav\u00e9s de material vegetal que arranha o olho.<\/li>\n<\/ul>\n<p>O desenvolvimento da bateria, <a href=\"http:\/\/www.emagine-eye.com\">dispositivos port\u00e1teis de reticula\u00e7\u00e3o<\/a> que pode ser utilizado em qualquer lugar, significa que o PACK-CXL pode ser levado at\u00e9 aos locais mais rurais, o que pode, em muitos casos, num \u00fanico tratamento, tratar eficazmente a infe\u00e7\u00e3o, salvando a vis\u00e3o destas pessoas. Tudo isto sublinha a import\u00e2ncia dos resultados deste ensaio hist\u00f3rico do PACK-CXL.<\/p>\n<p>Clique na imagem abaixo para <a href=\"https:\/\/rdcu.be\/cEyYb\">ver o PDF<\/a>.<\/p>\n<p><a href=\"https:\/\/rdcu.be\/cEyYb\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-36059 size-full\" src=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published-inline-image.png\" alt=\"Publica\u00e7\u00e3o do estudo de refer\u00eancia PACK-CXL \" width=\"660\" height=\"920\" srcset=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published-inline-image.png 660w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published-inline-image-215x300.png 215w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published-inline-image-9x12.png 9w\" sizes=\"(max-width: 660px) 100vw, 660px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Refer\u00eancia<\/strong><\/p>\n<p>Hafezi F, Hosny M, Shetty R, et al. PACK-CXL vs. terapia antimicrobiana para ceratite bacteriana, f\u00fangica e infecciosa mista: um ensaio prospetivo aleat\u00f3rio de fase 3. Eye Vis (Lond). 2022;9(1):2.<\/p>","protected":false},"excerpt":{"rendered":"<p>Hoje, foi publicado um estudo de refer\u00eancia sobre o PACK-CXL que demonstra que o PACK-CXL \u00e9 uma terapia eficaz contra a infe\u00e7\u00e3o da c\u00f3rnea.<\/p>","protected":false},"author":4,"featured_media":36058,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[243,214,95],"tags":[452,105,116,106,104],"class_list":["post-36057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-emilio-torres","category-farhad-hafezi","category-scientific-article","tag-clinical-trial","tag-corneal-infection","tag-corneal-ulcer","tag-keratitis","tag-pack-cxl"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Landmark PACK-CXL trial published - The ELZA Institute<\/title>\n<meta name=\"description\" content=\"Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.elza-institute.com\/pt\/landmark-pack-cxl-trial-published\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Landmark PACK-CXL trial published - The ELZA Institute\" \/>\n<meta property=\"og:description\" content=\"Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.elza-institute.com\/pt\/landmark-pack-cxl-trial-published\/\" \/>\n<meta property=\"og:site_name\" content=\"The ELZA Institute\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ELZA.Institute\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-12T12:15:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-15T09:22:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mark Hillen\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark Hillen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/\"},\"author\":{\"name\":\"Mark Hillen\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\"},\"headline\":\"Landmark PACK-CXL trial published\",\"datePublished\":\"2022-01-12T12:15:44+00:00\",\"dateModified\":\"2024-07-15T09:22:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/\"},\"wordCount\":501,\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg\",\"keywords\":[\"clinical trial\",\"Corneal infection\",\"Corneal ulcer\",\"Keratitis\",\"PACK-CXL\"],\"articleSection\":[\"Emilio Torres\",\"Farhad Hafezi\",\"Scientific article\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/\",\"url\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/\",\"name\":\"Landmark PACK-CXL trial published - The ELZA Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg\",\"datePublished\":\"2022-01-12T12:15:44+00:00\",\"dateModified\":\"2024-07-15T09:22:15+00:00\",\"description\":\"Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg\",\"width\":1200,\"height\":600,\"caption\":\"Landmark PACK-CXL phase 3 trial published\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.elza-institute.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emilio Torres\",\"item\":\"https:\/\/www.elza-institute.com\/de-ch\/emilio-torres\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Landmark PACK-CXL trial published\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.elza-institute.com\/#website\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"name\":\"The ELZA Institute\",\"description\":\"Swiss EyeCare at its finest\",\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.elza-institute.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.elza-institute.com\/#organization\",\"name\":\"The ELZA Institute\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"width\":1181,\"height\":453,\"caption\":\"The ELZA Institute\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ELZA.Institute\/\",\"https:\/\/x.com\/ELZA_Institute\",\"https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\",\"name\":\"Mark Hillen\",\"url\":\"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publica\u00e7\u00e3o do estudo de refer\u00eancia PACK-CXL - Instituto ELZA","description":"Hoje, foi publicado um estudo de refer\u00eancia sobre o PACK-CXL que demonstra que o PACK-CXL \u00e9 uma terapia eficaz contra a infe\u00e7\u00e3o da c\u00f3rnea.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.elza-institute.com\/pt\/landmark-pack-cxl-trial-published\/","og_locale":"pt_PT","og_type":"article","og_title":"Landmark PACK-CXL trial published - The ELZA Institute","og_description":"Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.","og_url":"https:\/\/www.elza-institute.com\/pt\/landmark-pack-cxl-trial-published\/","og_site_name":"The ELZA Institute","article_publisher":"https:\/\/www.facebook.com\/ELZA.Institute\/","article_published_time":"2022-01-12T12:15:44+00:00","article_modified_time":"2024-07-15T09:22:15+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg","type":"image\/jpeg"}],"author":"Mark Hillen","twitter_misc":{"Escrito por":"Mark Hillen","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#article","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/"},"author":{"name":"Mark Hillen","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15"},"headline":"Landmark PACK-CXL trial published","datePublished":"2022-01-12T12:15:44+00:00","dateModified":"2024-07-15T09:22:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/"},"wordCount":501,"publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"image":{"@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg","keywords":["clinical trial","Corneal infection","Corneal ulcer","Keratitis","PACK-CXL"],"articleSection":["Emilio Torres","Farhad Hafezi","Scientific article"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/","url":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/","name":"Publica\u00e7\u00e3o do estudo de refer\u00eancia PACK-CXL - Instituto ELZA","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage"},"image":{"@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg","datePublished":"2022-01-12T12:15:44+00:00","dateModified":"2024-07-15T09:22:15+00:00","description":"Hoje, foi publicado um estudo de refer\u00eancia sobre o PACK-CXL que demonstra que o PACK-CXL \u00e9 uma terapia eficaz contra a infe\u00e7\u00e3o da c\u00f3rnea.","breadcrumb":{"@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#primaryimage","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/01\/Landmark-pack-cxl-phase-3-trial-published.jpg","width":1200,"height":600,"caption":"Landmark PACK-CXL phase 3 trial published"},{"@type":"BreadcrumbList","@id":"https:\/\/www.elza-institute.com\/landmark-pack-cxl-trial-published\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.elza-institute.com\/"},{"@type":"ListItem","position":2,"name":"Emilio Torres","item":"https:\/\/www.elza-institute.com\/de-ch\/emilio-torres\/"},{"@type":"ListItem","position":3,"name":"Landmark PACK-CXL trial published"}]},{"@type":"WebSite","@id":"https:\/\/www.elza-institute.com\/#website","url":"https:\/\/www.elza-institute.com\/","name":"O Instituto ELZA","description":"Swiss EyeCare no seu melhor","publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.elza-institute.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/www.elza-institute.com\/#organization","name":"O Instituto ELZA","url":"https:\/\/www.elza-institute.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","width":1181,"height":453,"caption":"The ELZA Institute"},"image":{"@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ELZA.Institute\/","https:\/\/x.com\/ELZA_Institute","https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home"]},{"@type":"Person","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15","name":"Mark Hillen","url":"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/"}]}},"_links":{"self":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/36057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/comments?post=36057"}],"version-history":[{"count":0,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/36057\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media\/36058"}],"wp:attachment":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media?parent=36057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/categories?post=36057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/tags?post=36057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}